genedrive plc, the molecular diagnostics company, will be showcasing its molecular Genedrive® HCV ID Kit and Genedrive® platform at the International Liver Conference taking place in Amsterdam from 19th-23rd April 2017. Clinical validation data for Genedrive® HCV ID Kit will be presented at the meeting by Dr Darragh Duffy from the Institut Pasteur, Paris. The Genedrive® HCV ID Kit is a qualitative HCV assay, providing results within 90 minutes. The assay is designed for use in a decentralised testing environment and is performed on the company’s portable molecular diagnostics platform. The assay is performed directly from a small volume of plasma (25μl) and does not require a separate viral extraction process . The Genedrive® HCV assay recently demonstrated sensitivity of greater than 99% and specificity of 100% when compared to the Abbott Molecular RealTime HCV Assay. “The Genedrive® HCV assay will allow decentralised laboratories to provide affordable onsite molecular testing for HCV that aligns with recent WHO testing guidelines,” said David Budd, Chief Executive Officer of genedrive plc. “With the wider availability of generic direct acting antiviral agents, the drive in resource limited countries is to cost effectively identify and treat individuals with Hepatitis C. We believe that with the performance achieved by the Genedrive® HCV assay, there is an opportunity to play a very meaningful role in this strategy.”The company has recently submitted the Genedrive® HCV ID Kit for CE certification under the EU Medical Devices Directive. Anyone wishing to receive more information on the assay at launch can register their interest at https://www.genedrive.com/assays/hcv-assay.php.
Related articles
